Novo Nordisk's Danish Dilemma: Legal Clouds Gather as the Weight-Loss Pill Misses Its Mark
Published on 08/05/2026 at 13:32 | Redaktion boerse-global.de
The numbers tell a story of a company that raised its outlook yet still managed to disappoint. Novo Nordisk's shares have been caught in a pincer movement this week, squeezed between a legal setback in the United States and softer-than-expected sales of its much-hyped oral weight-loss drug.
After Tuesday's 5.85 percent slide that dragged the stock to 38.44 euros, Wednesday brought a modest rebound of 1.91 percent to 39.12 euros. But the damage has been done. Over seven trading days, the Danish pharmaceutical giant has shed 13.29 percent of its value, leaving it roughly 28.68 percent adrift of the 54.86-euro January peak. The market capitalization now stands at 181.30 billion euros.
A Pill That Was Supposed to Change Everything
The immediate trigger for the latest sell-off was the second-quarter performance of the oral version of Wegovy. The pill generated 3.22 billion Danish kroner in revenue — just shy of the 3.27 billion kroner analysts had pencilled in. The gap is marginal, but it lands on a product that Novo Nordisk has positioned as its great hope in the escalating battle with Eli Lilly for dominance in the obesity-treatment market.
Mizuho analyst Jared Holz captured the mood in a note to clients: the absence of upside surprises in Wegovy pill sales weighed on the stock. The company's own numbers underscore the mixed picture. Injectable Wegovy advanced 1 percent to 19.484 billion kroner, while Ozempic grew a healthier 3 percent to 31.375 billion kroner. Total quarterly revenue reached 78.49 billion kroner, up 3 percent at constant exchange rates.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
That headline growth masks a steeper sequential decline. The first quarter delivered 96.823 billion kroner, meaning the second quarter fell roughly 19 percent — a drop complicated by a one-off benefit in the year-ago period, when a rebate reversal from the 340B discount program added 2.6 billion kroner to the top line.
The Legal Front Reopens
While investors digested the pill's shortfall, a separate development threatened to keep Novo Nordisk in the headlines for months, possibly well into 2027. A US federal judge has allowed parts of a shareholder lawsuit to proceed toward discovery, ruling that investors had plausibly argued that statements about CagriSema's tolerability and the design of its late-stage trial may have been misleading.
The ruling establishes no guilt. It does not determine that Novo Nordisk committed securities fraud. But it opens the door to evidence-gathering, and that alone is enough to keep the CagriSema saga alive in the public consciousness.
The origins of this legal fight trace back to February, when trial data showed patients on CagriSema lost an average of 20.2 percent of their body weight — short of the 23.6 percent achieved by Eli Lilly's Tirzepatid. CagriSema thus failed its central objective of demonstrating non-inferiority to the rival treatment.
CEO Mike Doustdar has consistently pushed back on that interpretation. In an interview with CNBC, he argued the market had punished the data too harshly and promised that additional studies would paint a fuller picture. A company spokesperson has dismissed the lawsuit's allegations as unfounded, vowing a vigorous defense.
A Difficult Moment in a Difficult Year
The timing could hardly be worse. Novo Nordisk is fighting to restore investor confidence in its weight-loss franchise just as Eli Lilly accelerates its market share gains. The company is betting on a next-generation product pipeline — higher-dose Wegovy, oral formulations, and CagriSema itself — but every new legal filing and skeptical analyst note makes the search for a floor in the share price that much harder.
The technical picture reflects the strain. The 14-day relative strength index sits at 33.6, flirting with oversold territory without yet flashing a clear reversal signal. The stock trades below both its 50-day moving average of 40.97 euros and its 200-day average of 40.31 euros. Annualized volatility of 38.33 percent speaks to the nervousness gripping the trading floor.
The Buyback Continues
Amid the turbulence, Novo Nordisk has quietly pressed on with its share repurchase program. Through August 3, the company had bought back B-shares worth 7.5 billion kroner out of a total program of 15 billion kroner. Since launching the buyback on February 4, it has acquired roughly 27 million B-shares at an average price of 278.35 kroner each.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
The US Market Turns Hostile
Looking ahead, management has flagged expectations of declining US sales. The company cites current prescription trends for GLP-1 injections, intensifying competition, and a negative impact from reduced coverage of obesity medications under Medicaid. Eli Lilly's earnings report, released the same Wednesday, served as a reminder of the competitive pressure bearing down on the Danish group.
A Convergence of Troubles
What makes this moment particularly striking is not the single-day drop — pharma stocks routinely move 5 percent on news. It is the way problems have begun to compound. A scientific setback eroded confidence in the pipeline. That setback has now metastasized into litigation that could sustain uncertainty for years, arriving precisely when Novo Nordisk hoped to demonstrate that its turnaround was complete.
Clinical risk, intensifying competition, and now a legal battle: the combination weighs more heavily than any single missed quarterly figure. The discovery phase of the shareholder lawsuit is expected to surface new details in the coming months about internal communications and how CagriSema data was presented to investors. Until then, the stock remains what it has become — a paper searching for buyers while bad news from the lab, the courtroom, and the competitive arena feeds on itself.
Whether the Wegovy pill's prescription momentum can accelerate in coming quarters will likely determine if the raised annual guidance — now pointing to revenue ranging from a 6 percent decline to flat, rather than the earlier forecast of a 4 to 12 percent drop — proves sustainable. The pill has been prescribed more than 5 million times since its January launch, according to Doustdar. The question is whether that translates into the kind of growth that can lift a stock that has lost nearly a third of its value in seven months.
Ad
Novo Nordisk Stock: New Analysis - 5 August
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
